• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bridgebio Pharma Inc (NQ: BBIO )

    26.96 -2.02 (-6.97%)
    Streaming Delayed Price Updated: 3:28 PM EDT, Jun 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Bridgebio Pharma Inc

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    BridgeBio's Dwarfism Candidate Shows Favorable Height Increase, Safety Profile
    BridgeBio Pharma Inc (NASDAQ: BBIO) announced results from PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia, a genetic condition affecting a protein in the body called the... 
    Via Benzinga
    What's Going On With Kala Pharmaceuticals Shares Today
    Kala Pharmaceutical (NASDAQ: KALA) shares skyrocketed more than 20% Monday morning on higher-than-average volume. On an average market day, Kala shares trade about 2.5 million times throughout the... 
    Via Benzinga
    Kennedy-Wilson, Radian Group, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday
    U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    What's Going On With Avalon GloboCare Shares Today
    The overall market ticked slightly higher in pre-market trading Monday morning, but Avalon Globocare Corp (NASDAQ: ALBT) shares really took off. Avalon GloboCare is a biotech company headquartered in... 
    Via Benzinga
    Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
    U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose... 
    Via Benzinga
    Looking Into BridgeBio Pharma's Return On Capital Employed
    Via Benzinga
    Looking Into BridgeBio Pharma's Return On Capital Employed
    Via Benzinga
    BridgeBio Pharma: Q3 Earnings Insights
    BridgeBio Pharma (NASDAQ:BBIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
    The company is testing a drug for children with achondroplasia, a cause of dwarfism. 
    Via Investor's Business Daily
    Why BridgeBio Pharma Stock Is Hitting New 52-Week Highs Monday
    BridgeBio Pharma Inc (NASDAQ: BBIO) shares are ripping higher Monday morning after the company announced positive data for its phase 2 study of 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Shares Preliminary Data From Gene Therapy Candidate In Ultra Rare Disorder
    Via Benzinga
    LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial
    Via Benzinga
    BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma to Participate in February and March Investor Events
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
    Via Benzinga
    Why BridgeBio Pharma Stock Is Shooting Higher
    BridgeBio Pharma Inc (NASDAQ: BBIO) shares are trading higher by 16.77% to $7.87 Thursday afternoon after the company initiated its CALIBRATE Phase 3 study of Encaleret. What Else? 
    Via Benzinga
    BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
    Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. 
    Via Benzinga
    BridgeBio Pharma to Participate in November Investor Events
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.